Defining the future of treatment for people with immune-mediated diseases
Ouro Medicines is a clinical-stage biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases. Its lead program, OM336 (gamgertamig), is a BCMAxCD3 T cell engager in a basket study targeting multiple autoimmune conditions, and has received FDA Fast Track and Orphan Drug designations. In March 2026, Gilead Sciences announced an agreement to acquire Ouro for approximately $2.18 billion.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2025
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
